The mechanisms of SGLT2 inhibitors to improve renal outcomes in patients with type 2 diabetes include the inhibition of renal glucose reabsorption, reduction in blood pressure, amelioration of glucotoxicity, and induction of hemodynamic effects [44,45]. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.